olivLaw · European equity research
PRIM, S.A. PRM.MC
Spain · BME Madrid · ISIN ES0170884417 · Vertical: Listed companies from Spain
PRIM, S.A. is a Spanish orthopaedics and medical device group with orthopaedic centres and factories in Spain and Portugal, active since 1870 and incorporated as a public limited company in 1966. In fiscal 2025 the group generated 30.5 mn EUR of operating cash flow, showing its internal funding capacity while it keeps investing in capacity. Its relevance grows as public health systems and mutual insurers increasingly outsource the supply of prostheses and technical aids.
At the close of 05 Nov 2026, PRIM, S.A. (PRM.MC) stock was 12.35 EUR (+0.00% on the day), with market capitalisation 210.2 m EUR, P/E 12.6 on diluted EPS of 0.98 EUR over the last 12 months, dividend yield 3.80%, beta 0.23, 52-week range 12.30–13.85 EUR.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 38.1
- weak (30–45)
- Bollinger (20, 2)
- 12.25 – 12.76
- in the lower half of the band · %B 0.19 · band width 4.1%
- SMA 50 / 200
- 12.71 / 13.01
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.10 / -0.09
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | −2.4% | −0.6% | −1.7 pp | — |
| 3 months | −7.5% | −4.2% | −3.3 pp | — |
| 6 months | −6.4% | +4.3% | −10.8 pp | — |
| Year to date | −6.4% | +7.5% | −13.9 pp | — |
| 1 year | −10.8% | +9.9% | −20.8 pp | +6.7% |
| 3 years | +12.3% | +49.8% | −37.6 pp | +31.5% |
| 5 years | −14.5% | +42.8% | −57.4 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 2-quarter history (min 13.5, median 14.3, max 15.0; quarters with earnings only).
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 216.5 m | 233.1 m | 251.8 m |
| Revenue YoY | unavailable | +7.7% | +8.0% |
| Net income | 12.7 m | 10.9 m | 16.7 m |
| Net income YoY | unavailable | −13.8% | +52.8% |
| Diluted EPS | unavailable | 0.64 | 0.98 |
| Diluted EPS YoY | unavailable | unavailable | +53.1% |
| net % | 5.9% | 4.7% | 6.6% |
| Free cash flow | unavailable | unavailable | unavailable |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 18.3 m EUR
- Financial debt
- 7.2 m EUR
- Net debt
- -11.1 m EUR
- Equity
- 137.6 m EUR
- Total assets
- 196.5 m EUR
- Debt / equity
- 0.05x
- Current ratio
- 2.99x
- ROE
- 12.5%
- ROA
- 8.6%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 216.5 m | 233.1 m | 251.8 m | esef· 20 Oct 2026verified |
| Cost of revenue | 92.7 m | 104.3 m | 103.1 m | esef· 20 Oct 2026verified |
| Gross profit | 123.8 m ≈ | 128.8 m ≈ | 148.7 m ≈ | esef· 20 Oct 2026derived |
| Operating income | 16.0 m | 15.6 m | 22.3 m | esef· 20 Oct 2026verified |
| Interest expense | 826.4 k | 773.7 k | 537.7 k | esef· 20 Oct 2026verified |
| Pre-tax income | 17.0 m | 14.3 m | 21.8 m | esef· 20 Oct 2026verified |
| Income tax | 4.4 m | 3.4 m | 5.1 m | esef· 20 Oct 2026verified |
| Net income | 12.7 m | 10.9 m | 16.7 m | esef· 20 Oct 2026verified |
| Diluted EPS | — | 0.64 | 0.98 | esef· 20 Oct 2026verified |
| Dividend per share | — | 0.45 | 0.47 | esef· 20 Oct 2026derived |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 6.4 m | 9.6 m | 18.3 m | esef· 20 Oct 2026verified |
| Receivables | 62.0 m | 50.3 m | 50.1 m | esef· 20 Oct 2026verified |
| Inventories | 68.8 m | 70.4 m | 67.3 m | esef· 20 Oct 2026verified |
| Current assets | 144.5 m | 134.9 m | 140.9 m | esef· 20 Oct 2026verified |
| Property, plant & equipment, net | 17.6 m | 18.7 m | 21.1 m | esef· 20 Oct 2026verified |
| Goodwill | 9.5 m | 11.4 m | 11.5 m | esef· 20 Oct 2026verified |
| Intangibles (excl. goodwill) | 14.2 m | 12.8 m | 11.7 m | esef· 20 Oct 2026verified |
| Total assets | 200.1 m | 190.3 m | 196.5 m | esef· 20 Oct 2026verified |
| Accounts payable | 44.0 m | 38.2 m | 37.0 m | esef· 20 Oct 2026verified |
| Long-term debt | 8.5 m | 7.6 m | 7.2 m | esef· 20 Oct 2026verified |
| Current liabilities | 62.1 m | 49.4 m | 47.1 m | esef· 20 Oct 2026verified |
| Equity | 125.8 m | 128.9 m | 137.6 m | esef· 20 Oct 2026verified |
| Shares outstanding at year end | — | 17.1 m | 17.0 m | esef· 20 Oct 2026derived |
Cash flow · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Capex | 8.8 m | 0 | 1.3 m | esef· 20 Oct 2026verified |
| Investing cash flow | -3.7 m | -7.5 m | -10.1 m | esef· 20 Oct 2026verified |
| Financing cash flow | 10.5 m | -11.3 m | -11.6 m | esef· 20 Oct 2026verified |
| Dividends paid | 6.2 m | 7.6 m | 8.0 m | esef· 20 Oct 2026verified |
| Share repurchases | — | 0 | 434.7 k | esef· 20 Oct 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 43.8% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 210.2 m EUR
Key indicators
Coverage and freshness
Score by group
44% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 6.38 – 22.28 EUR.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (EUR per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E14.88 – 22.28 (Mid 19.48)18 companies used · median multiple 19.9x · quartiles 15.2x – 22.7xACS.MC, ADX.MC, AEDAS.MC, AENA.MC, AMS.MC, ANA.MC, CAF.MC, CLEO.MC, CMO.MC, DESA.MC, DIA.MC, EAT.MC, EDR.MC, ELE.MC, ENER.MC, ENO.MC, FAE.MC, FCC.MC
- Dividend discount (DDM)6.38 – 8.70 (Mid 7.36)
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 43.8% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 13.5% | 29 (vs peers) | 24% |
| Net margin · Quality | 6.6% | 54 (vs peers) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 41.5x | 100 (on a fixed band) | 14% |
| Current ratio · Balance sheet | 3.0x | 100 (on a fixed band) | 10% |
| P/E (TTM) · Valuation | 12.6x | 86 (vs peers) | 24% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | 4.0% | 57 (on a fixed band) | 14% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet100/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality38/100 · 2/3 factors with a value
- Returns· partial57/100 · 1/2 factors with a value
- Valuation· partial86/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
PRIM, S.A. (PRM.MC). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 251.8 m EUR in 2025; YoY growth 8.0%; net margin 6.6%; ROE 12.5%.
The estimated value range is 10.63–15.49 EUR per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 13.42 EUR, the price of 12.35 EUR leaves a potential of 8.7% (value / price − 1) and a margin of safety of 8.0% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 43.8% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Interest coverage: 41.5x
- Current ratio: 3.0x
- P/E (TTM): 12.6x
What contradicts it
- ROIC: 13.5%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA, FCF yield, Payout ratio (FCF).
Versus the vertical median
Listed companies from Spain · same country · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ELE.MCEndesa SA | 46.9 bn | 21.4 | 26.4% | 10.5% | +0.5% | +43% / +134% |
| AENA.MCAena S.m.e. SA | 42.6 bn | 19.9 | 24.2% | 34.0% | +8.9% | +21% / +79% |
| AMS.MCAmadeus It Group Sociedad Anonima | 26.2 bn | 19.8 | 26.9% | 20.5% | +6.1% | −6% / −5% |
| ACS.MCAcs Actividades De Construccion Y Servicios, S.A. | 21.9 bn | 23.0 | 19.9% | 1.9% | +19.7% | +7% / +134% |
| ANA.MCAcciona SA | 11.7 bn | 14.5 | 16.9% | 4.0% | +5.5% | +24% / +66% |
| FCC.MCFomento De Construcciones Y Contratas S.A. | 5.0 bn | 30.3 | 5.3% | 1.7% | +6.9% | −8% / −14% |
| DIA.MCDistribuidora Internacional De Alimentacion SA | 2.7 bn | 20.6 | 165.6% | 2.2% | −2.7% | +51% / +380,733% |
| CMO.MCCementos Molins S.A. | 2.5 bn | 13.6 | 14.3% | 18.0% | −3.1% | +31% / unavailable |
| ENO.MCElecnor SA | 2.4 bn | 21.9 | 10.5% | 2.5% | +15.1% | −3% / +58% |
| ALM.MCAlmirall S.A. | 2.4 bn | 51.1 | 3.1% | 4.2% | +12.4% | −11% / +32% |
| FAE.MCFaes Farma SA | 1.5 bn | 19.3 | 10.8% | 13.0% | +23.7% | +3% / +57% |
| AEDAS.MCAedas Homes SA | 1.0 bn | 17.1 | 57.8% | 7.0% | −24.8% | +0% / +38% |
| EDR.MCEdreams Odigeo SA | 574.4 m | 11.5 | 21.0% | 7.8% | −0.4% | +40% / −24% |
| EAT.MCAmRest Holdings SE | 506.0 m | 31.4 | 4.3% | 0.6% | +0.1% | −34% / −61% |
| ADX.MCAudax Renovables S.A. | 468.5 m | 23.9 | 9.3% | 1.0% | −5.4% | −23% / −18% |
| PRM.MCPrim, S.A. | 210.2 m | 12.6 | 12.5% | 6.6% | +8.0% | −5% / +18% |
| ATRY.MCAtrys Health, S.A. | 200.4 m | — | -49.5% | -71.1% | +8.5% | −3% / −29% |
| ENER.MCEcoener, S.A. | 175.6 m | 32.2 | 4.2% | 6.4% | +3.6% | −34% / −6% |
| ADZ.MCAdolfo Dominguez SA | 62.9 m | 38.3 | 9.0% | 1.2% | +1.8% | +39% / +40% |
| DESA.MCDesarrollos Especiales De Sistemas De Anclaje S.A. | 44.8 m | 9.2 | 152.3% | 10.0% | +2.2% | +19% / unavailable |
| EZE.MCGrupo Ezentis SA | 29.0 m | — | — | -9.3% | +147.2% | −30% / −37% |
| CLEO.MCCompañia Levantina De Edificacion Y Obras Publicas SA | 17.3 m | 14.4 | 4.1% | 3.4% | +13.4% | unavailable / unavailable |
| AYC.MCAyco Grupo Inmobiliario, S.A. | 16.4 m | — | -33.8% | — | −100.0% | unavailable / unavailable |
| EBRO.MCEbro Foods, S.A. | 3.0 m | 0.0 | 10.0% | 7.7% | −4.0% | −0% / +19% |
| A3M.MCAtresmedia Corporacion De Medios De Comunicacion, S.A. | — | — | 7.9% | 6.9% | −2.7% | +13% / +60% |
1- and 3-year price returns: for PRM.MC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (EUR)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 7.56 Total return -36% · Per year -36% | 13.34 Total return 12% · Per year 12% | 20.06 Total return 67% · Per year 67% |
| 3 years | 7.86 Total return -27% · Per year -10% | 15.56 Total return 39% · Per year 12% | 25.62 Total return 124% · Per year 31% |
| 5 years | 8.18 Total return -18% · Per year -4% | 18.15 Total return 71% · Per year 11% | 32.72 Total return 197% · Per year 24% |
- Exit P/E± 3.89
- Net margin± 2.72
- Annual revenue growth± 2.16
- Annual dilution± 0.23
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
PRIM, S.A. is a Spanish orthopaedics and medical device group with orthopaedic centres and factories in Spain and Portugal, active since 1870 and incorporated as a public limited company in 1966. In fiscal 2025 the group generated 30.5 mn EUR of operating cash flow, showing its internal funding capacity while it keeps investing in capacity. Its relevance grows as public health systems and mutual insurers increasingly outsource the supply of prostheses and technical aids.
SWOT
Strengths
- Long operating history, extensive orthopaedic centre network and in-house manufacturing capacity.
- Solid equity base and rising operating cash flow.
- Experience in taking part in public tenders through temporary business associations.
Weaknesses
- High dependence on public funding and contracts with mutual insurers.
- Activity concentrated in the Spanish market, with limited presence outside the Iberian Peninsula.
- Integration of recent acquisitions may absorb management resources.
Opportunities
- Growing demand for technical aids linked to population ageing.
- Expansion in Italy and Portugal through the acquired companies.
- Development of the geriatric residence activity provided for in the corporate purpose.
Threats
- Price pressure in public tenders could reduce margins.
- Delays in administration payments may affect cash flow.
- Competition from large European suppliers and local distributors.
Risks
- Dependence on public contractshigh
Revenue depends heavily on winning and renewing tenders with mutual insurers and public bodies, which can be lost or changed.
- Late paymentsmedium
Long administrative payment terms can strain liquidity and working capital.
- Acquisition integrationmedium
Recent acquisitions in Italy and in the laboratory segment could generate unforeseen integration costs.
- Currency exposurelow
Activity in Portugal and Italy brings exposure to exchange-rate moves, visible in currency differences in cash flows.
- Health regulationmedium
Changes to medical device rules and prescription conditions could affect the product range and compliance costs.
Investment thesis
What would need to be true (bull case)
- If operating cash flow stays near its fiscal 2025 level, the group could fund investments and dividends without significant new borrowing.
- An ageing population could support long-term demand for orthopaedics and technical aids.
- Experience in temporary business associations could help win new contracts with mutual insurers.
What would break the thesis
- If public funding tightens, delayed payments could weigh on cash flow and margins.
- Concentration on the Spanish market could leave the group exposed to regulatory changes there.
- Integrating recent acquisitions could delay the synergies that are expected.
What to watch
- Trend in operating cash flow and collection periods2026
- Tender outcomes and renewal of mutual insurer contracts2026
- Integration of the acquired companies in Italy2026
- Dividend policy relative to investment spendingnext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The group is headquartered in Fuencarral (Madrid) and operates through the parent and subsidiaries, including Establecimientos Ortopédicos Prim, Laboratorios Herbitas, Teyder, EasyTech in Italy and Prim Produtos de Saúde in Portugal 1. Its corporate purpose covers manufacturing, sale and distribution of orthopaedic and medico-surgical material, as well as the construction and management of geriatric residences and real estate operations 1. Activity is carried out from factories, orthopaedic centres and delegations spread across Spain and Portugal 1.
An important part of the business model is the temporary business associations (UTE) through which the group supplies orthoprosthetic material and technical aids to accident and occupational disease mutual insurers and public bodies, usually under public tenders 1. These UTEs are consolidated proportionally to the participation share, typically 50% or 70% 1.
The capital structure evolved in 2025: total equity reached 137.6 mn EUR and the group paid dividends of 7.98 mn EUR 1. The company invested over 12 mn EUR in property, plant, intangibles and other investments in 2025 1.
Segments
Orthopaedics and prosthetics
The main segment comprises the orthopaedic centres and the supply of external prostheses, orthoses and technical aids, delivered through the centre network in Spain and through contracts with mutual insurers 1.
Devices and laboratories
Laboratorios Herbitas, Grupo Led 3D and the manufacturing subsidiaries in Petrer, Valencia and Sant Vicenç dels Horts produce or finish customised devices and components, which feed both the group's own network and third-party customers 1.
Market context
The group's main market is Spain, where demand for prostheses and technical aids depends on public funding, mutual insurer tenders and the health system 1. Activity in Portugal and Italy is much smaller but growing through recent acquisitions 1.
Operating cash flow rose significantly in 2025, which points to better conversion of public contracts, although sensitivity to the administration's payment terms remains a feature of the sector 1.
Trends
- Public tenders and long-term contractsmixed
Mutual insurers and public bodies award contracts through tenders, which gives visibility but also pressure on prices and payment conditions 1.
- Ageing populationtailwind
Rising demand for orthopaedics and technical aids linked to an older population could support long-term volumes if public funding stays stable 1.
- Pressure on public financesheadwind
Budget constraints in the health system could slow payments and reduce supplier margins, which would affect cash conversion 1.
- Consolidation through acquisitionsmixed
Acquisitions such as those in Italy and in the laboratory segment widen geographic and product reach, but also bring integration risks 1.
Competitive position
The group competes with other Spanish and European orthopaedic and medical device suppliers, as well as national distributors that win the same public tenders 1. Its position depends on its centre network and its ability to take part in mutual insurer tenders.
- Ottobock
German orthopaedics and prosthetics maker active in similar European markets.
- Össur
Icelandic prosthetics and orthopaedics company with a presence in Europe.
- Spanish orthopaedic distributors
Domestic firms that compete for the same contracts with mutual insurers.
- Large European general medical suppliers
Groups with medical product lines that can enter orthopaedic tenders.
News & filings
In the press
- Cum rămâne cu ROBOR? Dosarul ROBOR revine în prim-plan. Încep să apară decizii în instanţă în speţa bănci vs Consiliul Concurenţei. Curtea de Apel respinge cererea CEC Bank de suspendare a executării deciziei CC, dar banca poate face recurs. Iar BNR reafirmă că „nu consideră că există vreun motiv de revizuire a cadrului normativ” privind ROBORZiarul Financiar · 05 Nov 2026 · RO
- Nvidia pierde peste 8%, iar AMD se prăbuşeşte cu 16%. Investitorii încep să se teamă că boom-ul centrelor de date din SUA ar putea încetini. Victoria democraţilor aduce în prim-plan riscul unor noi restricţii, iar UBS estimează că 30% din capacitatea planificată pentru 2028 ar putea fi afectatăZiarul Financiar · 05 Nov 2026 · RO
- Prim-ministrul italian Giorgia Meloni avertizează că UE riscă irelevenţa în negocierile de pace cu privire la Ucraina, cerând stabilirea unui negociator cu mandatFinancial Intelligence (RO) · 05 Nov 2026 · RO
- LIVE TEXT/ Conferința prim-ministrului Vasile Tofan privind „rezultatele Guvernului după primele 100 de zile”Ziarul de Gardă (MD) · 05 Nov 2026 · RO
- Avion de pasageri pe ruta Dublin - Roma, deviat de urgență după o amenințare cu bombă. Ce spune prim-ministrul francez - ZIUA de ConstantaSurge — Google News · 05 Nov 2026 · RO
- /PROMO/ Prim-ministrul Vasile Tofan vine la „Cutia Neagră”: De la 20:00, la TV8!TV8 (MD) · 05 Nov 2026 · RO
- Prim-ministrul a propus ca Airbus să coopereze la dezvoltarea ecosistemului aviatic din Vietnam. - Vietnam.vnSurge — Google News · 04 Nov 2026 · RO
- Bursa de la Bucureşti închide pe plus, cu acţiunile Nuclearelectrica în prim-plan după anunţul privind repornirea reactorului 1. Rompetrol Rafinare scade pentru a cincea zi la rând cu 15%Ziarul Financiar · 04 Nov 2026 · RO
- Bursa de la Bucureşti închide pe plus, cu Nuclearelectrica în prim-plan după anunţul privind repornirea reactorului 1. Rompetrol Rafinare scade pentru a cincea zi la rând cu 15%Ziarul Financiar · 04 Nov 2026 · RO
- Comunitatea internațională sărbătorește înfrângerea republicanilor în SUA. Prim-ministrul britanic afirmă că “avem șansa să oprim războiul din Orientul Mijlociu”, iar Iranul amenință că “va urma un coșmar” dacă americanii nu opresc conflictul. Politicienii francezi îi cer lui Donald Trump “să-și reducă implicarea pe plan internațional și să admită că sunt necesare schimbări”. Premierul Spaniei: “Poporul american a votat împotriva urii”.Biziday.ro · 04 Nov 2026 · RO
- Prim-ministrul a solicitat Airbus să înființeze un centru de reparații a aeronavelor în Long Thanh, Gia Binh. - Vietnam.vnSurge — Google News · 04 Nov 2026 · RO
- Prim-ministrul îl primește pe președintele executiv internațional al Airbus Group. - Vietnam.vnSurge — Google News · 04 Nov 2026 · RO
- Alegeri SUA: Democrații "fură" un prim mandat din Senat republicanilor - Ziare.comSurge — Google News · 04 Nov 2026 · RO
- Alegeri intermediare în Statele Unite: Democrații „fură” un prim mandat din Senat republicanilor - DW.comDW (Deutsche Welle) — Europe · 04 Nov 2026 · EN
- Gabriel-Ioan Avrămescu, Prim-vicepreședintele ASF: ETF-urile pot juca un rol important în dezvoltarea pieței de capital; Potențialul de creștere rămâne ridicatFinancial Intelligence (RO) · 04 Nov 2026 · RO
- Continuă perchezițiile în cadrul operațiunii „Jupiter”. Un prim bilanț indică prejudicii de peste 26 de milioane de leiMediafax · 04 Nov 2026 · RO
- Alegeri intermediare în Statele Unite: Democrații „fură” un prim mandat din Senat republicanilor - DW.comSurge — Google News · 04 Nov 2026 · RO
- UPDATE - Alegeri în SUA. Lupta pentru controlul Congresului rămâne deschisă. Democraţii reuşesc să ia un prim loc de la republicani în Senat - News.roSurge — Google News · 04 Nov 2026 · RO
- Alegeri în SUA. Lupta pentru controlul Congresului rămâne deschisă. Democraţii reuşesc să ia un prim loc de la republicani în Senat - News.roSurge — Google News · 04 Nov 2026 · RO
- Niculescu: Pentru deciziile care se iau în şedinţele de guvern miniştrii vin cu propuneri, dar responsabilitatea e a prim-ministruluiDigi24 · 03 Nov 2026 · RO
Annual reports (ESEF)
- Annual report 202520 Oct 2026
- Annual report 202520 Oct 2026
- Annual report 202408 May 2025
- Annual report 202408 May 2025
Sources
- [1] Annual report, fiscal year ended 2025-12-31 (ESEF) · SEC / PRIM, S.A. · 31 Dec 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.